Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 622-626

  Grillo M J ^a   De Miguel, M J ^a   Munoz P M ^a   Marin C M ^a   Ariza, J ^b   Blasco, J M ^a  

^a Instituto Agroalimentario de Aragón IA2   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antimicrobial therapy; B. melitensis Rev 1 vaccine strain; Human brucellosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; DOXYCYCLINE; GENTAMICIN; REIG JOFRE; RIFAMPICIN; STREPTOMYCIN; VIBRAVENOSA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BRUCELLA MELITENSIS; BRUCELLOSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; EXPERIMENTAL INFECTION; FEMALE; INOCULATION; MOUSE; MOUSE STRAIN; NONHUMAN; SPLEEN; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BRUCELLA MELITENSIS; BRUCELLOSIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 33747872648     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl289     Document Type: Article

References (25)

1. Blasco JM. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 1997; 31: 275-83.
2. Alton GG, Elberg SS. Rev 1 Brucella melitensis vaccine. A review of ten years of study. Vet Bull 1967; 37: 793-800.
3. Berkelman RL. Human illness associated with use of veterinary vaccines. Clin Infect Dis 2003; 37: 407-14.
4. Blasco JM, Diaz R. Brucella melitensis Rev 1 vaccine as a cause of human brucellosis. Lancet 1993; 342: 805.
5. Squarcione S, Maggi P, Lo Caputo S et al. A case of human brucellosis caused by accidental injection of animal vaccine. G Ital Med Lav 1990; 12: 25-6.
6. Solera J, Rodríguez-Zapata M, Geijo P et al. Doxycycline-rifampin versus doxycycline-streptomycn in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 1995; 39: 2061-7.
7. Solera J, Espinosa A, Martínez-Alfaro E et al. Treatment of Human Brucellosis with Doxycycline and Gentamicin. Antimicrob Agents Chemother 1997; 41: 80-4.
8. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier Curchill Livingstone, 2005; 2669-74.
9. Herzberg M, Elberg S. Immunization against Brucella infection: I. Isolation and characterization of a streptomycin-dependent mutant. J Bacteriol 1953; 66: 585-99.
10. Alton GG, Jones LM, Angus RD et al. Techniques for the Brucellosis Laboratory. Paris: Institut National de la Recherche Agronomique, 1988.
11. Sham DF, Washington II JA. Antibacterial susceptibility tests: Dilution methods. 5th edn. Manual of Clinical Microbiology 1991; 1105-16.
12. Domingo S, Gastearena I, Vitas AI et al. Comparative activity of azithromycin and doxycycline against Brucella spp infection in mice. J Antimicrob Chemother 1995; 36: 647-56.
13. Bowden RA, Racaro GC, Baldi PC. Effect of early antibiotic treatment on the antibody response to cytoplasmic proteins of Brucella melitensis in mice. Clin Diagn Lab Immunol 1999; 6: 440-3.
14. Gamazo C, Prior S, Irache JM et al. Treatment of experimental brucellosis with gentamicin entrapped in liposomal and microsphere formulations. Recent Res Devel Antimicrob Chemother 1999; 3: 59-82.
15. Grilló MJ, Manterola L, de Miguel MJ et al. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine 2006; 24: 2910-6.
16. Ariza J, Bosch J, Gudiol F et al. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother 1986; 30: 958-60.
17. Braibant M, Guilloteau L, Zygmunt MS. Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family. Antimicrob Agents Chemother 2002; 46: 3050-3.
18. Morita Y, Kodama K, Shiota S et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 1998; 42: 1778-82.
19. Cloeckaert A, Grayon M, Grepinet O. Identification of Brucella melitensis vaccine strain Rev. 1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine 2002; 20: 2546-50.
20. Bjorkman J, Samuelson P, Anderson DL et al. Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium. Mol Microbiol 1999; 31: 53-8.
21. Finken M, Kirschner P, Meier A et al. Molecular basis of streptomycin resistance in Mycobacyterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutation within a functional 16S ribosomal RNA psedoknot. Mol Microbiol 1993; 9: 1239-46.
22. Maisnier-Patin S, Berg OG, Liljas L et al. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 2002; 2: 355-66.
23. Gill AE, Aymes SG. The contribution of a novel ribosomal aminoglycoside resistance of Escherichia coli mutants. J Chemother 2004; 16: 347-9.
24. Bosch J, Liñares J, López de Goicoechea MJ et al. In vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother 1986; 17: 459-61.
25. Prior S, Gander B, Irache JM et al. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J Antimicrob Chemother 2005; 55: 1032-6.